A Phase I study with repeated doses of the Multiple Ascending Dose of RMC-035
Phase of Trial: Phase I
Latest Information Update: 14 Nov 2018
Price : $35 *
At a glance
- Drugs RMC 035 (Primary)
- Indications Acute kidney injury; Preeclampsia; Radiation injuries
- Focus Adverse reactions
- 14 Nov 2018 New trial record
- 09 Nov 2018 According to an A1M Pharma AB media release, the Swedish Medicines Agency has given permission to initiate the Phase I clinical trial of ROSgard. Single Ascending Dose part is expected to start in the first quarter of 2019 and Multiple Ascending Dose part in the second half of 2019.
- 01 Nov 2018 According to an A1M Pharma AB media release, this study is expected to be initiated during the second half of 2019, and results are expected in the first quarter of 2020.